1. What Is Fibronectin?

1.1 Basic Definition of Fibronectin

Fibronectin (FN) is a large adhesive glycoprotein encoded by the human FN1 gene. It is widely distributed in the blood, tissue interstitium, and extracellular matrix.

Fibronectin exists in two principal forms in the human body.

① Plasma fibronectin is synthesized mainly by hepatocytes and circulates in plasma as a soluble dimer. Following tissue injury and blood coagulation, plasma fibronectin can become incorporated into the blood clot and participate in the formation of the early provisional matrix.

② Cellular fibronectin is secreted by multiple cell types, including fibroblasts and endothelial cells. It is initially released in a soluble form and subsequently undergoes extension and assembly under the influence of integrins and cell-generated traction forces, forming insoluble fibronectin fibrils.

The precursor mRNA of FN1 undergoes alternative splicing, primarily involving extra domain A (EDA), extra domain B (EDB), and the type III connecting segment (IIICS), also known as the V region. Cellular fibronectin exhibits greater splice-form diversity and may contain EDA, EDB, and different forms of IIICS, whereas normal plasma fibronectin generally lacks EDA and EDB. These alternatively spliced regions can alter fibronectin structure and cellular responses. The fibronectin composition of normal adult tissues differs from that found during embryonic development, wound repair, and fibrosis.

1.2 Relationship Between Fibronectin and the Extracellular Matrix

The extracellular matrix (ECM) is a three-dimensional structure composed of collagen, elastin, fibronectin, laminin, proteoglycans, glycosaminoglycans, and other components. The ECM is not an inert material that merely fills the spaces between cells. It provides structural support to tissues while regulating cell adhesion, migration, survival, and differentiation through integrins and other cell-surface receptors.

Different ECM components perform different primary functions:

① Collagen primarily provides tensile strength and structural support;

② Elastin enables tissues to return to their original shape after deformation;

③ Proteoglycans and glycosaminoglycans participate in the binding of water, ions, and signaling molecules;

④ Laminin primarily contributes to basement membrane formation and epithelial-cell attachment;

⑤ Fibronectin primarily connects cells with multiple ECM components and participates in provisional matrix formation and matrix organization.

A distinctive feature of fibronectin is its ability to bind both cell-surface integrins and extracellular molecules, including collagen, fibrin, heparin-like carbohydrate chains, and certain growth factors. Its importance lies in regulating how cells connect to and interact with the surrounding matrix.

2. Molecular Structure of Fibronectin

2.1 Dimeric Structure and Repeating Modules

Full-length fibronectin is generally composed of two similar polypeptide chains. Each chain has a molecular mass of approximately 220–250 kDa. The two chains are linked by disulfide bonds at their carboxyl termini, producing a total molecular mass of approximately 440–500 kDa.

Each fibronectin chain is composed primarily of three types of repeating modules:

① Fibronectin type I repeats (FNI);

② Fibronectin type II repeats (FNII);

③ Fibronectin type III repeats (FNIII).

Human fibronectin generally contains 12 FNI modules, 2 FNII modules, and 15–17 FNIII modules. Variation in the number of FNIII modules results mainly from alternative splicing involving regions such as EDA and EDB.

This modular structure enables fibronectin to connect multiple molecules simultaneously and integrate cell adhesion, matrix binding, and fibril assembly.

2.2 Why Are FNIII Modules Particularly Important?

FNI and FNII modules contain internal disulfide bonds and are therefore relatively structurally stable. FNIII modules consist primarily of β-sheet structures and generally lack internal disulfide bonds, making them more responsive to mechanical tension.

When cells pull on fibronectin through integrins, some FNIII modules may undergo extension, relative rotation, or partial unfolding. These changes may alter the distance between adjacent binding sites and expose regions that were previously less accessible.

Fibronectin can therefore transmit two types of information simultaneously:

① Biochemical information: specific amino acid sequences bind to integrins or other molecules;

② Mechanical information: force-induced conformational changes in fibronectin influence cell adhesion and matrix assembly.

Fibronectin is therefore an ECM protein whose conformation and assembly state can change in response to cell-generated traction forces.

2.3 Does Structure Determine Performance?

The amino acid sequence and domain composition of fibronectin determine which receptors and matrix molecules it can theoretically bind and therefore provide the structural basis for its biological functions.

However, in actual raw materials and formulations, structural composition alone cannot predict final performance. Whether fibronectin retains biological activity also depends on:

① Whether the protein is correctly folded;

② Whether key binding sites remain exposed;

③ Whether adjacent domains maintain the appropriate spatial arrangement;

④ Whether the target cells express the relevant integrins;

⑤ Whether the protein has undergone degradation, aggregation, or interfacial adsorption;

⑥ Whether the topically applied protein can reach responsive cells.

Therefore, detecting fibronectin in a formulation demonstrates only that the relevant protein or fragments are present. It does not directly prove that the protein retains complete cell-adhesion and matrix-assembly activity.

3. The Cell-Binding Domain and the RGD Sequence

3.1 What Is the Cell-Binding Domain?

The core cell-binding region of fibronectin is located within the adjacent FNIII9 and FNIII10 modules.

FNIII10 contains the arginine-glycine-aspartic acid sequence, abbreviated Arg-Gly-Asp or RGD. RGD can bind to multiple integrins and is a central recognition motif through which fibronectin mediates cell adhesion.

The adjacent FNIII9 module contains the proline-histidine-serine-arginine-asparagine sequence, abbreviated Pro-His-Ser-Arg-Asn or PHSRN, which is commonly referred to as the synergy site.

High-affinity binding to the α5β1 integrin generally depends on all of the following:

① The RGD sequence in FNIII10 provides the principal binding site;

② The PHSRN sequence in FNIII9 enhances binding stability and receptor selectivity;

③ FNIII9 and FNIII10 maintain an appropriate distance and spatial orientation.

The cell-binding domain is therefore not an isolated short peptide. It is a receptor-recognition region formed jointly by critical amino acid sequences and their three-dimensional arrangement.

3.2 Why Can RGD Not Represent Full-Length Fibronectin?

Short RGD peptides can bind to certain integrins and are therefore commonly used to modify cell-culture materials and biomaterial surfaces. However, RGD reproduces only part of the receptor-binding functions of fibronectin.

Full-length fibronectin also performs the following important functions:

① Collagen Binding

Fibronectin can bind to collagen or denatured collagen through specific FNI and FNII domains, contributing to the connection and organization of different ECM components.

② Fibrin Binding

Following injury, plasma fibronectin can bind to fibrin and become cross-linked under the action of activated coagulation factor XIII, forming a provisional matrix that supports cell attachment.

③ Heparin and Proteoglycan Binding

Regions including FNIII12–14 can bind to heparin and heparan sulfate carbohydrate chains, thereby influencing interactions between fibronectin, cell-surface proteoglycans, and the surrounding ECM.

④ Growth-Factor Binding

Certain fibronectin domains, particularly the FNIII12–14 region, can bind selected members of the platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) families. These interactions influence the local retention and presentation of growth factors within the matrix.

Fibronectin does not thereby become a growth factor itself. Instead, it regulates the conditions under which growth factors encounter their cellular receptors.

⑤ Cell-Traction-Dependent Fibril Assembly

Full-length fibronectin can extend and assemble into fibrils under integrin-mediated and cytoskeleton-generated tension. An isolated RGD peptide generally does not possess this complete fibril-assembly capacity.

4. How Fibronectin Regulates Cell Behavior

4.1 Is Fibronectin a “Cellular Messenger”?

Fibronectin is not a classical soluble cellular messenger. Growth factors, hormones, and cytokines can generally diffuse through body fluids or interstitial fluid and initiate signaling after binding to their corresponding receptors. Fibronectin, by contrast, functions mainly as an extracellular matrix ligand.

Fibronectin is an adhesive ligand for integrins and a mechanosignaling regulatory protein that connects the ECM, integrins, and the cytoskeleton. It enables cells to sense whether an adhesive matrix is present and to detect the density, organization, and mechanical loading of that matrix.

4.2 How Do Integrins Convert Fibronectin Binding into Cellular Signals?

The principal process through which fibronectin influences cell behavior can be represented as follows:

Fibronectin FNIII9–10 → RGD/PHSRN binding to integrins → integrin clustering → focal adhesion formation → reorganization of the cytoskeleton and signaling proteins → changes in cell adhesion, spreading, migration, and survival

After integrins bind to fibronectin, they cluster within the cell membrane and recruit focal-adhesion proteins, including talin, kindlin, and vinculin, to the intracellular side of the membrane.

Signaling molecules such as focal adhesion kinase (FAK) and Src-family kinases may then become activated and, depending on the cell type and surrounding environment, influence:

① The phosphoinositide 3-kinase/protein kinase B pathway (PI3K/Akt), which is primarily involved in cell survival;

② The mitogen-activated protein kinase/extracellular signal-regulated kinase pathway (MAPK/ERK), which participates in gene-expression and proliferation regulation;

③ Rho-family small GTPases, which regulate the cytoskeleton, cellular contraction, and the direction of migration.

These pathways are not activated simultaneously or to the same degree in all cell types. The actual response depends on the integrin subtype, cellular state, fibronectin conformation, and growth-factor environment.

4.3 How Do Cells, in Turn, Modify Fibronectin?

Integrins not only transmit fibronectin-derived signals into the cell but also transfer forces generated by the actin cytoskeleton back to fibronectin.

Cell-generated traction can extend relatively compact fibronectin molecules, expose regions required for fibronectin self-assembly, and promote the deposition of additional fibronectin molecules into fibrils. Fibronectin assembly also affects the deposition and stability of collagen and other ECM components.

Fibronectin and cells therefore engage in bidirectional regulation:

Fibronectin alters cellular adhesion and mechanical loading, while cell-generated traction forces alter fibronectin conformation and fibril assembly.

5. How Fibronectin Participates in Cutaneous Wound Healing

Wound healing involves overlapping phases of hemostasis, inflammation, proliferation, and tissue remodeling. Fibronectin performs different functions during these phases.

5.1 Hemostasis: Formation of a Provisional Fibrin–Fibronectin Matrix

Following skin injury, thrombin cleaves fibrinogen to generate fibrin, which can then polymerize. In the presence of thrombin and Ca²⁺, coagulation factor XIII is activated to form coagulation factor XIIIa (FXIIIa).

FXIIIa is a transglutaminase that forms isopeptide bonds between glutamine and lysine residues in proteins. When fibronectin is cross-linked to fibrin, it can enhance cellular adhesion to the blood clot and provide a provisional attachment structure for cells that subsequently enter the wound.

5.2 Re-Epithelialization: Supporting Keratinocyte Migration

Keratinocytes at the wound edge must transition from their original stable attachment state, establish front-rear polarity, and migrate toward the center of the wound.

Fibronectin provides dynamic adhesion sites through integrins. Cells form new adhesions at the leading edge, release existing adhesions at the trailing edge, and use traction generated by the actin cytoskeleton to move forward.

Cell migration does not become progressively faster as adhesion strength increases:

① If adhesion is too weak, cells cannot generate sufficient traction;

② If adhesion is too strong, the trailing edge cannot detach efficiently;

③ Moderate and dynamic adhesion is more favorable for sustained migration.

RGD, PHSRN, integrin subtype, and fibronectin density all contribute to this balance.

5.3 Granulation Tissue Formation: Fibroblast Adhesion and ECM Organization

After fibroblasts enter the wound, they synthesize cellular fibronectin, collagen, and other ECM components. Fibronectin fibrils generally increase before a mature collagen network is established and primarily participate in:

① Providing adhesion sites for fibroblasts;

② Transmitting cell-generated traction forces;

③ Influencing the deposition and alignment of collagen and other ECM components;

④ Regulating the local retention and presentation of certain growth factors.

Animal wound studies have shown that specifically engineered fibrin–fibronectin matrices can enhance repair responses involving keratinocytes, fibroblasts, and endothelial cells and accelerate wound closure in mice.

These studies provide a biological rationale for the use of fibronectin in wound dressings and tissue-engineering materials. However, they do not directly demonstrate that fibronectin in conventional skincare products can produce the same effects in intact skin.

5.4 Tissue Remodeling: Renewal of the Fibronectin Network During Healing

As the wound gradually closes, the early fibrin and fibronectin provisional matrix is degraded, reorganized, and progressively replaced by a more mature ECM. Collagen subsequently becomes the principal load-bearing component.

An appropriate increase in fibronectin during the relevant stages can support repair, whereas persistently elevated fibronectin may be associated with scar formation and fibrotic responses.

For example, fibronectin containing the EDA domain can influence the recruitment of latent transforming growth factor-β-binding protein into the ECM and is associated with transforming growth factor beta 1 (TGF-β1) signaling, myofibroblast activation, and fibrotic responses. The effects of fibronectin on wound healing therefore depend on the timing of its expression, spatial distribution, splice form, and the mechanical state of the tissue.

6. Differences Among Fibronectin, Laminin, and Ceramides

All three may be associated with “skin repair,” but they differ in molecular class, site of action, and principal mechanism.

6.1 Laminin and Fibronectin

Laminin is a major structural protein of basement membranes. Laminin-332 in the skin, for example, is composed of α3, β3, and γ2 chains and can bind to integrins including α3β1 and α6β4.

Laminin-332 participates in the formation of hemidesmosomes and other cell-adhesion structures. It helps basal epidermal keratinocytes attach to the basement membrane and maintains the mechanical stability of the dermal–epidermal junction. Fibronectin, by contrast, is more extensively involved in the interstitial ECM and in the formation of the provisional matrix following injury, where it primarily regulates cell migration, traction-force transmission, and ECM organization.

The principal differences between the two are:

① Fibronectin is more strongly associated with dynamic cell migration and tissue reconstruction;

② Laminin is more strongly associated with basement membrane structure and stable epithelial-cell attachment.

6.2 Ceramides and Fibronectin

Ceramides are formed when a sphingoid base is linked to a fatty acid through an amide bond. Their simplified structure can be represented as:

Sphingoid base—NH—CO—fatty acid chain

Together with cholesterol and free fatty acids, ceramides form the organized intercellular lipid structures of the stratum corneum. Ceramide subtype, fatty-acid-chain length, and the proportions of these three lipid classes all influence lipid organization and skin-barrier function.

Therefore:

① Ceramides primarily replenish and reconstruct the lipid structure of the stratum corneum;

② Fibronectin primarily regulates adhesion between cells and the ECM and contributes to tissue reconstruction.

For ordinary dryness, excessive cleansing, or insufficient stratum corneum lipids, the mechanism of action of ceramides is more direct. Fibronectin cannot replace ceramides in replenishing stratum corneum lipids.

7. Can Fibronectin Improve Facial Redness and Visible Capillaries?

7.1 Different Types of Skin Redness Must First Be Distinguished

The condition commonly described as “visible red capillaries” or “facial redness” may include several different problems:

① Temporary redness caused by barrier impairment or irritation;

② Short-term erythema following light- or energy-based procedures;

③ Persistent telangiectasia;

④ Inflammation and neurovascular abnormalities associated with rosacea.

Redness caused by barrier impairment and short-term erythema following light- or energy-based procedures is generally associated with inflammation, increased local blood flow, and elevated transepidermal water loss.

If a formulation supports restoration of the skin barrier and reduces persistent irritation, erythema may diminish as the condition of the skin improves.

Persistent telangiectasia, however, involves structural changes in blood vessels and abnormalities in vasomotor regulation. Fibronectin is not a vasoconstrictor, and there is currently no reliable evidence that topical fibronectin can close already dilated superficial blood vessels.

7.2 What Evidence Is Available from Human Studies?

A 28-day split-face study published in 2026 enrolled 32 healthy Chinese women undergoing intense pulsed light (IPL) treatment. One side of each participant’s face received a recombinant human fibronectin serum as reported in the study, while the other side received the same base formulation without fibronectin.

During the first 7 days, participants used a repair serum labeled in the study as containing 50 μg/mL recombinant human fibronectin. From Days 8 to 28, they used a maintenance serum labeled as containing 25 μg/mL recombinant human fibronectin.

Compared with the control side, the fibronectin-treated side showed the following findings at certain assessment points:

① Higher stratum corneum hydration;

② Lower transepidermal water loss (TEWL);

③ Objective erythema measurements showed that the proportion of red areas was more favorable on the fibronectin-treated side on Day 3, while the a* value was more favorable on Day 7. By Day 28, neither of these objective erythema measures differed significantly from the control side, although investigator-assessed erythema scores continued to indicate greater improvement on the fibronectin-treated side;

④ No treatment-related adverse reactions were reported during the study.

Because the control side received the same base formulation without fibronectin, the study supports an association between the fibronectin-containing product, under this specific formulation and application regimen, and improvements in certain post-IPL barrier parameters and short-term erythema recovery.

The available evidence is most appropriately interpreted as indicating that a specific fibronectin-containing formulation may support short-term recovery after IPL treatment. It should not be extrapolated to mean that fibronectin can treat rosacea or directly eliminate persistent telangiectasia.

8. Fibronectin Stability and Formulation Applications

8.1 Raw-Material Form Determines the Range of Functions That May Be Retained

“Fibronectin” used in skincare products and biomaterials may refer to different raw-material forms.

8.2 Principal Factors Affecting Fibronectin Stability

Fibronectin is a large, conformation-sensitive protein whose stability may be affected by the following factors. The magnitude of each effect depends on whether the raw material is full-length fibronectin, a recombinant domain fragment, or a hydrolyzed peptide mixture and should therefore be determined using actual data from the specific raw material and final formulation:

① Temperature: elevated temperatures may induce partial unfolding and aggregation;

② pH and ionic strength: these may alter protein charge and intermolecular interactions;

③ Shear and foaming: these increase the opportunity for the protein to contact the air–liquid interface;

④ Oil–water interfaces and packaging surfaces: these may cause protein adsorption and conformational changes;

⑤ Freeze–thaw cycles and long-term storage: these may promote aggregation or loss of activity;

⑥ Proteases: these may cleave key functional domains;

⑦ Formulation excipients: surfactants, preservatives, chelating agents, and thickeners may all affect the state of the protein.

8.3 What Must Be Controlled During Formulation Development?

The manufacturing process for a fibronectin formulation should generally be established on the basis of stability data for the specific raw material. Reasonable development principles include:

① Adding the protein during an appropriate low-temperature stage to minimize unnecessary heat exposure;

② Controlling high-shear homogenization, prolonged mixing, and excessive foaming;

③ Selecting the pH, buffer system, and ionic strength according to raw-material data;

④ Separately assessing the effects of preservatives, surfactants, thickeners, and chelating agents;

⑤ Evaluating freeze-drying and reconstitution, dual-chamber packaging, or single-dose packaging where required for stability;

⑥ Reassessing protein structure and biological activity after long-term and accelerated stability testing.

“Acceptable protein content” does not necessarily mean that “protein function remains intact.” After formulation and storage, receptor-binding or cell-adhesion activity must also be evaluated.

8.4 Limitations Imposed by Intact Skin on Large Proteins

Full-length fibronectin is a macromolecule with a molecular mass of several hundred kilodaltons. The normal stratum corneum substantially limits the passive penetration of molecules of this size.

It cannot be assumed solely from cell-culture experiments that topically applied full-length fibronectin can cross the stratum corneum and directly reach dermal fibroblasts.

In cell-culture experiments, fibronectin is generally coated directly onto the culture surface, allowing cells to contact it without an intervening barrier. Conventional topical products, by contrast, must contend with the physical barrier formed by the stratum corneum. These two experimental conditions are not equivalent.

8.5 How Can the Actual Activity of a Fibronectin Product Be Evaluated?

The evaluation of fibronectin raw materials and finished products can be divided into four levels.

① Confirm the Identity of the Raw Material

The source, amino acid sequence, molecular mass, purity, expression system, and retained domains should be clearly defined.

② Assess Structural Integrity

The protein should be evaluated for degradation, aggregation, and conformational changes. Depending on the properties of the raw material, suitable methods may include electrophoresis, size-exclusion chromatography, circular dichroism spectroscopy, and differential scanning calorimetry

③ Evaluate Biological Activity

Integrin-binding, cell-adhesion, cell-spreading, or cell-migration assays may be used to confirm whether the key cell-binding structures remain functional.

④ Verify the Finished Product

After the protein has been incorporated into the complete formulation and subjected to actual storage conditions, its structure and biological activity should be reassessed.

Human efficacy studies should also correspond to the product’s actual conditions of use, intended population, and proposed claims.

9. Representative Chemicals Related to Research on Fibronectin Structure, Cell Adhesion, Wound Repair, and the Skin Barrier

Table 1. Extracellular Matrix, Cell Adhesion, and Integrin Research

Table 2. Coagulation, Provisional Fibrin Matrix, and Anticoagulant Regulation Research

Table 3. Comparative Research on Stratum Corneum Lipids and the Skin Barrier

Note: The products listed above are representative Aladdin products related to scientific research and formulation development. Additional information on product specifications, grades, and certificates of analysis may be obtained by searching the Aladdin website using the product name, CAS number, or catalog number.

References

[1] Dalton CJ, Lemmon CA. Fibronectin: molecular structure, fibrillar structure and mechanochemical signaling. Cells. 2021;10(9):2443. doi:10.3390/cells10092443.

[2] Leahy DJ, Aukhil I, Erickson HP. 2.0 Å crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region. Cell. 1996;84(1):155-164. doi:10.1016/S0092-8674(00)81002-8.

[3] Martino MM, Hubbell JA. The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. FASEB Journal. 2010;24(12):4711-4721. doi:10.1096/fj.09-151282.

[4] Sottile J, Hocking DC. Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions. Molecular Biology of the Cell. 2002;13(10):3546-3559. doi:10.1091/mbc.E02-01-0048.

[5] Corbett SA, Lee L, Wilson CL, Schwarzbauer JE. Covalent cross-linking of fibronectin to fibrin is required for maximal cell adhesion to a fibronectin-fibrin matrix. Journal of Biological Chemistry. 1997;272(40):24999-25005. doi:10.1074/jbc.272.40.24999.

[6] Gimeno-LLuch I, Benito-Jardón M, Guerrero-Barberà G, Burday N, Costell M. The role of the fibronectin synergy site for skin wound healing. Cells. 2022;11(13):2100. doi:10.3390/cells11132100.

[7] Poblete Jara C, Wang O, do Prado TP, Ismail A, Fabian FM, Li H, et al. Novel fibrin-fibronectin matrix accelerates mice skin wound healing. Bioactive Materials. 2020;5(4):949-962. doi:10.1016/j.bioactmat.2020.06.015.

[8] Klingberg F, Chau G, Walraven M, Boo S, Koehler A, Chow ML, et al. The fibronectin ED-A domain enhances recruitment of latent TGF-β-binding protein-1 to the fibroblast matrix. Journal of Cell Science. 2018;131(5):jcs201293. doi:10.1242/jcs.201293.

[9] Adair-Kirk TL, Griffin GL, Meyer MJ, Kelley DG, Miner JH, Keene DR, et al. Keratinocyte-targeted expression of human laminin γ2 rescues skin blistering and early lethality of laminin γ2 deficient mice. PLoS ONE. 2012;7(9):e45546. doi:10.1371/journal.pone.0045546.

[10] Uche LE, Gooris GS, Bouwstra JA, Beddoes CM. Increased levels of short-chain ceramides modify the lipid organization and reduce the lipid barrier of skin model membranes. Langmuir. 2021;37(31):9478-9489. doi:10.1021/acs.langmuir.1c01295.

[11] Feng H, Ge L, Shi G, Yu S, Wang X, Li X, et al. Fibronectin-based skin care regimens for skin recovery after intense pulsed light therapy: a split-face study. Clinical, Cosmetic and Investigational Dermatology. 2026;19:564788. doi:10.2147/CCID.S564788.

[12] Pereira P, Kelly SM, Cooper A, Mardon HJ, Gellert PR, van der Walle CF. Solution formulation and lyophilisation of a recombinant fibronectin fragment. European Journal of Pharmaceutics and Biopharmaceutics. 2007;67(2):309-319. doi:10.1016/j.ejpb.2007.03.009.

[13] Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology. 2000;9(3):165-169. doi:10.1034/j.1600-0625.2000.009003165.x.

For more related articles, see below:

Applicability Comparison of Vitronectin, Laminin and Fibronectin in Cell Culture Coating Systems

Antibody simulation experiments based on the framework of fibronectin type III structural domains

Cosmetic Peptides

Resveratrol

Ferulic Acid: Structural Features, Preparation Routes, and Key Points for Research Applications

Role of Sphingolipid Metabolic Remodeling in Apoptotic and Inflammatory Signaling

Cosmetic Grade Explained

How to decipher the whitening code?

Niacin (Vitamin B3): Structural Features, Metabolic Roles, and Application Landscape

The "Six Key Checkpoints" of Skin Lightening

Tyrosinase: a key regulatory enzyme in melanin synthesis and its biological and applied significance

Glutathione (GSH) Quantification: Method Systems, Experimental Workflows, and Key Quality-Control Considerations

Glutathione Reductase: A Flavin-Dependent Reductive System Maintaining GSH/GSSG Homeostasis, with Assays and Applications

What is Glutathione？

What Is Glutathione Agarose?

Enzymatic Hydroxylation Mechanism of Salicylate Conversion to Catechol